
|Articles|March 1, 2010
Use of testosterone therapy in hypogonadal men with prostate cancer
Just a few years ago, it would have been unthinkable to offer testosterone therapy (TTh) to men with a history of prostate cancer. Yet several changes have occurred to make TTh a reasonable treatment option in men who are symptomatic from testosterone deficiency.
Advertisement
Key Points
The relationship between T and prostate cancer has been a primary interest of mine, and it has been fascinating to watch the transformation in thought and practice over the last 20 years. In this article, I will present our current understanding of this topic and its impact on clinical practice.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











